NeuroSense Therapeutics
NRSN
9 hedge funds and large institutions have $694K invested in NeuroSense Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, 2 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
83% more capital invested
Capital invested by funds: $380K → $694K (+$314K)
80% more funds holding
Funds holding: 5 → 9 (+4)
0.13% more ownership
Funds ownership: 1.42% → 1.54% (+0.13%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$238K |
| 2 |
Jane Street
New York
|
+$104K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$29K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$23.8K |
| 5 |
FIA
FNY Investment Advisers
New York
|
+$2.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$184K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$135K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$38K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$14.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.43K |
NRSN Hedge Fund Activity: Q1 2022 in Review
9 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q1 2022, worth a combined $694K — up 83% from $380K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NRSN positions and 3 closed out — a net gain of 4 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $238K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $184K sold.
- 9 institutional investors held NeuroSense Therapeutics (NRSN) as of Q1 2022, up from 5 in Q4 2021.
- Funds reported $694K of NeuroSense Therapeutics stock for Q1 2022, up 83% quarter-over-quarter.
- 7 funds opened new NeuroSense Therapeutics positions in Q1 2022 and 3 closed out, a net change of +4 holders.
- The largest NeuroSense Therapeutics buyer in Q1 2022 was Ikarian Capital, an estimated $238K added.
- The largest NeuroSense Therapeutics seller in Q1 2022 was Hudson Bay Capital Management, an estimated $184K sold.
Based on aggregated 13F filings for Q1 2022.